Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA

SHANGHAI, China, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced that the China National...
November 14, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab and Novocure Awarded Deal of the Year

SHANGHAI, China, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, and Novocure Limited (NASDAQ: NVCR) today announced that...
November 07, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Limited Announces Presentations at November Conferences

SHANGHAI, China, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that members of the senior management team...
October 22, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong

ZEJULA is the first and only PARP inhibitor approved in Hong Kong for the maintenance treatment of platinum-sensitive relapsed ovarian cancer irrespective of BRCA mutation status Zai Lab expects to...
September 27, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence

Mr. Fu will oversee global business development, discovery, manufacturing and other operational activities in newly-created role Mr. Fu will lead expansion of U.S. operations and establish Zai Lab’s...
September 26, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology

SHANGHAI, China, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, presented results of its open-label study to evaluate the...
September 26, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology

Results demonstrate anti-tumor activity and manageable safety profile of the two dosing regimens of ZL-2301 tested in the trial Plan to pursue study to evaluate ZL-2301 in combination with anti-PD-1...
September 25, 2018 07:30 ET | Source: Zai Lab Limited

Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable

SHANGHAI, China, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that senior management will participate in a...
September 12, 2018 16:20 ET | Source: Zai Lab Limited

Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China

SHANGHAI, China, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, will host a conference call and webcast to discuss its...
September 05, 2018 20:59 ET | Source: Zai Lab Limited

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

SHANGHAI, China, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced the pricing of...